Latest news with #VenturaSecurities
Mint
a day ago
- Business
- Mint
Bull Case Forecast: Sensex may hit 1,15,836 and Nifty 43,876 by FY28, says Ventura
Indian equity market is likely to deliver strong gains over the next few years, with the benchmark indices potentially rising 42 percent by fiscal 2028, according to Ventura Securities. Despite a turbulent global economic backdrop, the brokerage sees India's strong GDP growth, manageable debt levels, and relatively stable bond yields as key drivers positioning the country ahead of global peers. In its latest forecast, Ventura Securities said that the Sensex could reach 1,15,836 and the Nifty 50 could climb to 43,876 by FY28 in a bullish scenario. These projections are supported by a compound annual earnings per share (EPS) growth rate of 12–14 percent and macroeconomic stability. Even in a more conservative or bearish environment, the brokerage sees solid upside. It estimates the Sensex could still rise to 104,804 points and the Nifty 50 to 39,697. The forecast is underpinned by a price-to-earnings (PE) multiple of 21 times in the bull case and 19 times in the bear case, with estimated FY28 EPS at 5,516 for the Sensex and 2,089 for the Nifty. According to Ventura, India's unique macroeconomic combination — relatively high growth, moderate debt, and benign interest rates — gives it an edge over advanced economies like the US and Japan. 'India's large growth market is likely to outpace its global peers supported by a unique combination of strong GDP growth, moderate debt levels, and comparatively benign bond yields,' the brokerage noted. Ventura's bullish outlook is also shaped by encouraging Q1FY26 earnings season trends. As of mid-quarter, 159 companies have declared their results, with broad-based growth across sectors. Engineering, manufacturing, and services led the charge, while consumption, commodities, and pharmaceuticals delivered steady performances. Sectors such as BFSI, IT, healthcare, and logistics have delivered positive earnings surprises. This, Ventura said, highlights the resilience of Indian corporate earnings and reinforces confidence in long-term fundamentals. 'India remains the world's most promising investment destination,' the brokerage added, citing GDP growth at 6.5 percent, a debt-to-GDP ratio around 80%, and stable bond yields. While developed markets face headwinds such as high debt and sluggish growth, India's demographic dividend and structural economic reforms continue to attract global capital. Vinit Bolinjkar, Head of Research at Ventura Securities, said the past decade has proven India's resilience despite multiple crises. 'In the last 10 years, the Indian economy has demonstrated resilience and clocked the highest GDP growth among large economies, despite global headwinds such as the NBFC crisis, COVID-19, Russia–Ukraine war, and the recent uncertainty on Trump tariffs,' he said. According to Bolinjkar, India's ability to mitigate risks will outweigh existing challenges and help push GDP growth to an estimated 7.3 percent by FY30. Strategic measures like the discovery of oil in the Andaman region, the gold monetization scheme, and a multi-pronged national security strategy are expected to add further strength to India's macroeconomic fundamentals. Ventura believes that the Indian equity market has not yet priced in the long-term structural advantages the country offers. Factors such as rising foreign exchange reserves, sustainable debt levels, and the possibility of lower interest rates could create a highly favorable investment landscape in the coming years. In this context, the Sensex's journey to 115,000 and beyond looks achievable — provided the current momentum in earnings and reforms continues. For investors looking beyond short-term volatility, India stands out as a resilient and rewarding long-term bet. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Economic Times
24-06-2025
- Business
- Economic Times
Global Civil Projects IPO opens today: Check price band, GMP, subscription and other details
Investors can bid for a minimum of 211 shares per lot, translating into an investment of Rs 14,981 at the upper end. Global Civil Projects' Rs 119 crore IPO opens for subscription today, with a price band of Rs 67–71 per share. The Delhi-based EPC player, focused on government urban infrastructure, plans to use the proceeds for working capital, machinery purchase, and strategic expansion. Strong order book and improving margins back the 'Subscribe' call from Ventura Securities. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Should you subscribe? The Rs 119 crore initial public offering (IPO) of Global Civil Projects Ltd opens for subscription today and will close on June 26. The Delhi-based infrastructure EPC firm , with a focus on government contracts for urban infrastructure such as roads, bridges, flyovers, and sewerage systems, is offering 1.67 crore fresh equity shares in the price band of Rs 67–71 per can bid for a minimum of 211 shares per lot, translating into an investment of Rs 14,981 at the upper end. Ahead of the issue opening, the GMP is Rs company plans to use the proceeds to fund working capital requirements (Rs 75 crore), purchase construction machinery (Rs 14.3 crore), and for general corporate purposes, including potential acquisitions (Rs 29.7 crore). The equity shares will be listed on both the NSE and of FY24, Global Civil Projects has executed over 55 projects and has an outstanding order book of over Rs 900 crore. The company reported revenue of Rs 334.8 crore and net profit of Rs 15.4 crore in FY24, with PAT rising over 216% margin stood at 14.13%, and return on equity improved to 19.8%. Post-issue, promoter holding will come down from 88.1% to 63.4%.Ventura Securities has given a 'Subscribe' rating to the IPO, citing the company's execution capabilities, improving profitability, and strong presence in public infrastructure. 'With a track record of timely execution and a robust government pipeline, GCP is well-placed to scale,' the brokerage flagged risks such as geographical concentration and subcontractor dependency but noted that rising public capex and the company's positioning make it a credible long-term opportunity.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Mint
23-06-2025
- Business
- Mint
Indian benchmarks drop 1% as investors fret over heightened Mideast tensions
(Reuters) -India's equity benchmarks fell 1% on Monday after U.S. attacks on Iranian nuclear sites fuelled fears of a further escalation in Middle East tensions and pushed oil prices to a five-month high. The Nifty 50 and the BSE Sensex were down 0.9% each at 24,890.03 points and 81,659.09 points, respectively, as of 10:37 a.m. IST. All 13 major sectors traded lower. The broader mid-caps fell 0.2% and small-caps were flat. The U.S. bombed Iranian nuclear sites over the weekend, joining Israel in the biggest Western military action against the Islamic Republic since the 1979 revolution. Most Asian stocks fell on Monday, with the MSCI Asia ex Japan down more than 1%. Oil prices briefly hit a five-month high, while the focus remains on a potential military response from Iran. [MKTS/GLOB] "Worries over potential supply disruptions from Strait of Hormuz is driving the sentiment," said Vinit Bolinjkar, head of research at Ventura Securities. About a fifth of the world's total oil consumption passes through the strait, which lies between Oman and Iran. Higher crude oil prices are a negative for India, which depends heavily on imports for its energy requirements, as they could stoke inflation and widen the fiscal deficit. Still, UBS said it does not see a prolonged disruption to oil supplies. "We believe that near-term downside in stocks could represent an opportunity for investors who are underallocated to equities to build positions," the brokerage said. Meanwhile, IT stocks shed 1.8% after Accenture posted a third consecutive quarter of yearly decline in outsourcing orders as a cutback in U.S. government spending and tariff uncertainty pressured economic growth. Indian IT firms get a significant chunk of their revenue from the U.S. In contrast, small finance banks rose after the central bank reduced the mandated portion of lending to priority sectors to 60% from 75%. (Reporting by Vivek Kumar M; Editing by Sonia Cheema and Mrigank Dhaniwala)
Mint
13-06-2025
- Business
- Mint
From ₹19 to ₹299, this stock soars 1475% in 5 years; Ventura sees another 53% upside
Multibagger stock Wanbury has emerged as one of the most astonishing success stories on Dalal Street, transforming itself from an obscure penny stock into a headline-maker in five years. From trading at just ₹ 19 in June 2020, the stock has surged more than 1,475 percent to hover around ₹ 299.35 in recent sessions. This translates to a remarkable ₹ 1 lakh investment growing to over ₹ 15.75 lakh. Over the past year alone, Wanbury has rallied nearly 93 percent, delivering impressive returns to investors in a staggered but consistent manner. The multibagger stock has climbed 4 percent in June so far, following a 25.5 percent gain in May, a 1 percent rise in April, and an eye-catching 37 percent surge in March. Despite facing setbacks earlier this year—dropping 25 percent in January and 21 percent in February—Wanbury has bounced back strongly, showcasing persistent buying interest. The stock hit its 52-week high of ₹ 330 last month and its 52-week low of ₹ 151.10 in July 2024. From its Covid-era lows of ₹ 18 per share, the stock has multiplied nearly 1,565 percent — cementing its multibagger credentials. Domestic brokerage Ventura Securities has initiated coverage on Wanbury Ltd with a bullish 'buy' rating, setting a price target of ₹ 458 over the next 24 months. With the stock currently around ₹ 299.35, this target implies a potential upside of 53 percent. Ventura sees robust earnings potential, backed by strong growth in both its API and branded formulations segments. According to the brokerage, Wanbury's revenue is projected to grow at a CAGR of 20 percent from FY25 to FY28, reaching ₹ 1,046 crore. EBITDA and net profit are expected to post even sharper growth at 33 percent and 51 percent CAGR, respectively. By FY28, the company's EBITDA is expected to touch ₹ 177 crore, with net profit at ₹ 104 crore. Margins, too, are set to expand — EBITDA margin is seen improving by 310 basis points to 15.5 percent, while net margin may increase by 290 basis points to 10 percent. As per the brokerage, Wanbury's strength lies in its leadership in Active Pharmaceutical Ingredients (APIs), with a global market share of 10 percent in Metformin and 30 percent in Sertraline. The API division, which largely caters to export markets, is expected to grow at a 16 percent CAGR, reaching ₹ 819 crore by FY28. Its domestic branded formulations business is growing at an even faster clip. Focused on high-margin chronic therapies, this segment is projected to expand at a 47 percent CAGR to ₹ 227 crore by FY28, driven by new product launches and broader customer outreach, it further stated. The company is also recovering from past setbacks, particularly its troubled Spanish formulations venture. A return to profitability in FY24 and positive net worth indicate a successful turnaround. Ventura attributes Wanbury's revival to operational efficiencies and strategic debt refinancing. Looking ahead, Ventura pointed out that the company has allocated ₹ 165 crore for a brownfield expansion at its Tanuku plant, expected to be implemented between FY26 and FY28. This aligns with its strategy of maintaining an asset-light model while scaling up production capabilities.
Mint
13-06-2025
- Business
- Mint
From ₹19 to ₹299, this stock soars 1475% in 5 years; Ventura sees another 53% upside
Multibagger stock Wanbury has emerged as one of the most astonishing success stories on Dalal Street, transforming itself from an obscure penny stock into a headline-maker in five years. From trading at just ₹ 19 in June 2020, the stock has surged more than 1,475 percent to hover around ₹ 299.35 in recent sessions. This translates to a remarkable ₹ 1 lakh investment growing to over ₹ 15.75 lakh. Over the past year alone, Wanbury has rallied nearly 93 percent, delivering impressive returns to investors in a staggered but consistent manner. The multibagger stock has climbed 4 percent in June so far, following a 25.5 percent gain in May, a 1 percent rise in April, and an eye-catching 37 percent surge in March. Despite facing setbacks earlier this year—dropping 25 percent in January and 21 percent in February—Wanbury has bounced back strongly, showcasing persistent buying interest. The stock hit its 52-week high of ₹ 330 last month and its 52-week low of ₹ 151.10 in July 2024. From its Covid-era lows of ₹ 18 per share, the stock has multiplied nearly 1,565 percent — cementing its multibagger credentials. Domestic brokerage Ventura Securities has initiated coverage on Wanbury Ltd with a bullish 'buy' rating, setting a price target of ₹ 458 over the next 24 months. With the stock currently around ₹ 299.35, this target implies a potential upside of 53 percent. Ventura sees robust earnings potential, backed by strong growth in both its API and branded formulations segments. According to the brokerage, Wanbury's revenue is projected to grow at a CAGR of 20 percent from FY25 to FY28, reaching ₹ 1,046 crore. EBITDA and net profit are expected to post even sharper growth at 33 percent and 51 percent CAGR, respectively. By FY28, the company's EBITDA is expected to touch ₹ 177 crore, with net profit at ₹ 104 crore. Margins, too, are set to expand — EBITDA margin is seen improving by 310 basis points to 15.5 percent, while net margin may increase by 290 basis points to 10 percent. As per the brokerage, Wanbury's strength lies in its leadership in Active Pharmaceutical Ingredients (APIs), with a global market share of 10 percent in Metformin and 30 percent in Sertraline. The API division, which largely caters to export markets, is expected to grow at a 16 percent CAGR, reaching ₹ 819 crore by FY28. Its domestic branded formulations business is growing at an even faster clip. Focused on high-margin chronic therapies, this segment is projected to expand at a 47 percent CAGR to ₹ 227 crore by FY28, driven by new product launches and broader customer outreach, it further stated. The company is also recovering from past setbacks, particularly its troubled Spanish formulations venture. A return to profitability in FY24 and positive net worth indicate a successful turnaround. Ventura attributes Wanbury's revival to operational efficiencies and strategic debt refinancing. Looking ahead, Ventura pointed out that the company has allocated ₹ 165 crore for a brownfield expansion at its Tanuku plant, expected to be implemented between FY26 and FY28. This aligns with its strategy of maintaining an asset-light model while scaling up production capabilities. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
